Cited by 393Adrenal and Paraganglionic TumorsNeuroendocrine Tumor Research AdvancesRenal cell carcinoma treatment

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma

Open access

Kimura, Noriko, Takayanagi, Ryoichi, Takizawa, Nae, Itagaki, Eiji, Katabami, Takayuki, Kakoi, Narihiko, Rakugi, Hiromi, Ikeda, Yukihiro, Tanabe, Akiyo, Nigawara, Takeshi, Ito, Sadayoshi, Kimura, Itaru, Naruse, Mitsuhide, _, _·2014·Endocrine Related Cancer

DOI 10.1530/erc-13-0494

Open this paper in CoChat — free account Open PDF

Abstract

Phaeochromocytomas (PHEO) and paragangliomas are rare catecholamine-producing tumours. Although 10-30% of these tumours metastasise, histopathological criteria to discriminate malignant from benign tumours have not been established; therefore, reliable histopathological markers predicting metastasis are urgently required. A total of 163 tumours, including 40 metastatic tumours, collected by the Phaeochromocytoma Study Group in Japan (PHEO-J) were analysed using a system called grading system for adrenal phaeochromocytoma and paraganglioma (GAPP). The tumours were scored based on GAPP criteria as follows: histological pattern, cellularity, comedo-type necrosis, capsular/vascular invasion, Ki67 labelling index and catecholamine type. All tumours were scored from 0 to 10 points and were graded as one of the three types: well-differentiated (WD, 0-2 points), moderately differentiated (MD, 3-6 points) and poorly differentiated (PD, 7-10 points). GAPP scores of the non-metastatic and metastatic groups were 2.08±0.17 and 5.33±0.43 (mean±s.e.m., P<0.001) respectively. There was a significant negative correlation between the GAPP score and the interval until metastasis (r=-0.438, P<0.01). The mean number of years until metastasis after the initial operation was 5.5±2.6 years. The study included 111 WD, 35 MD and 17 PD types. The five-year survival of these groups was 100, 66.8 and 22.4% respectively. In addition, negative immunoreactivity for succinate dehydrogenase gene subunit B (SDHB) was observed in 13 (8%) MD or PD tumours and ten of the 13 (77%) had metastases. Our data indicate that a combination of GAPP classification and SDHB immunohistochemistry might be useful for the prediction of metastasis in these tumours.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1530/erc-13-0494

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Distinct Clinical Features of Paraganglioma Syndromes Associated With <EMPH TYPE="ITAL">SDHB</EMPH> and <EMPH TYPE="ITAL">SDHD</EMPH> Gene Mutations
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893
Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases
Thompson, L. D. R. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200205000-00002 · Cited by 715
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis
van Nederveen, F. H., Gaal, J., Favier, J., Korpershoek, E., Oldenburg, R. A., de Bruyn, E. M., Sleddens, H. F. B. M., Derkx, P., Rivière, J., Dannenberg, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70164-0 · Cited by 554
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez‐Roqueplo, A., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Kien, P. K. V., Corvol, P. L., Plouin, P., & Jeunemaı̂tre, X. (2003) · PubMed · Cited by 542
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
Castro‐Vega, L. J., Buffet, A., de Cubas, A. A., Cascón, A., Menara, M., Khalifa, E., Amar, L., Azriel, S., Bourdeau, I., Chabre, O., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt639 · Cited by 412
Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status
Eisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K. T., Timmers, H. J. L. M., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.016 · Cited by 375
The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas
Burnichon, N., Rohmer, V., Amar, L., Herman, P., Leboulleux, S., Darrouzet, V., Niccoli, P., Gaillard, D. A., Chabrier, G., Chabolle, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2504 · Cited by 374
Histopathology of benign versus malignant sympathoadrenal paragangliomas: Clinicopathologic study of 120 cases including unusual histologic features
Linnoila, R. I., Keiser, H. R., Steinberg, S. M., & Lack, E. E. (1990) · Human Pathology · doi:10.1016/0046-8177(90)90155-x · Cited by 373
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Chrisoulidou, A., Kaltsas, G., Ilias, Ι., & Grossman, A. B. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0074 · Cited by 310
AFIP Atlas of Tumor Pathology
Start, R. D. (2000) · Histopathology · doi:10.1046/j.1365-2559.2000.01097.x · Cited by 304

Flagged first, then by citations

Show all 25 references

Research works printed but not linked: 5

Gimenez-Roqueplo, 2003, Cancer Research, 63, 5615
2013, Molecular and cellular endocrinology, 386, 92
Nagura, 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 12, 1107
2011, Endocrine Reviews, 32
1991, ARCHIVES OF PATHOLOGY LABORATORY MEDICINE, 115, 484

Sorted by citations

Items 101–200 of 391

Advances in Adrenal and Extra-adrenal Paraganglioma: Practical Synopsis for Pathologists
Juhlin, C. C., & Mete, Ö. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000365 · Cited by 20
Validation and Evaluation of 5 Scoring Systems for Predicting Metastatic Risk in Pheochromocytoma and Paraganglioma
Li, Q., Lan, Z., Jiang, Y., Wang, R., Li, Z., & Jiang, X. (2024) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002238 · Cited by 19
Pheochromocytoma and paraganglioma: from treatment to follow-up
Aygün, N. (2020) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.14744/semb.2020.58998 · Cited by 19
In Vivo Fluorescence Imaging and Urinary Monoamines as Surrogate Biomarkers of Disease Progression in a Mouse Model of Pheochromocytoma
Ullrich, M., Bergmann, R., Peitzsch, M., Cartellieri, M., Qin, N., Ehrhart‐Bornstein, M., Block, N. L., Schally, A. V., Pietzsch, J., Eisenhofer, G., et al. (2014) · Endocrinology · doi:10.1210/en.2014-1431 · Cited by 19
Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas
Castro, M. A., Sanz, Í. G., Ojeda, C. M., Hanzu, F. A., Mora, M., Vicente, A., Carrera, C. B., Novoa, P. D. M., García, M. D. C. L., Lamas, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1279828 · Cited by 18
Mediastinal paraganglioma successfully resected by robot-assisted thoracoscopic surgery with en bloc chest wall resection: a case report
Shidei, H., Maeda, H., Isaka, T., Matsumoto, T., Yamamoto, T., Nagashima, Y., & Kanzaki, M. (2020) · BMC Surgery · doi:10.1186/s12893-020-00701-2 · Cited by 17
An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
Inaki, A., Shiga, T., Tsushima, Y., Jinguji, M., Wakabayashi, H., Kayano, D., Akatani, N., Yamase, T., Kunita, Y., Watanabe, S., et al. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01699-0 · Cited by 17
Urinary Bladder Paragangliomas: Analysis of Succinate Dehydrogenase and Outcome
Gupta, S., Zhang, J., Rivera, M., & Erickson, L. A. (2016) · Endocrine Pathology · doi:10.1007/s12022-016-9439-2 · Cited by 16
Images in Endocrine Pathology: Progressive Loss of Sustentacular Cells in a Case of Recurrent Jugulotympanic Paraganglioma over a Span of 5 years
Zhou, Y. Y., Coffey, M., Mansur, D. B., Wasman, J. K., Asa, S. L., & Couce, M. (2020) · Endocrine Pathology · doi:10.1007/s12022-020-09632-3 · Cited by 16
New and Emerging Biomarkers in Endocrine Pathology
Papathomas, T. G., & Nosé, V. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000227 · Cited by 16
Clinical and Pathological Tools for Predicting Recurrence and/or Metastasis in Patients with Pheochromocytoma and Paraganglioma
Bima, C., Bioletto, F., Lopez, C., Bollati, M., Arata, S., Procopio, M., Gesmundo, I., Ghigo, E., Maccario, M., & Parasiliti‐Caprino, M. (2022) · Biomedicines · doi:10.3390/biomedicines10081813 · Cited by 15
Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma
Lee, S. E., Oh, E., Lee, B., Kim, Y. J., Oh, D., Jung, K., Choi, J., Kim, J., Kim, S. J., Yang, J. W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8234 · Cited by 15
N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease
Leijon, H., Kaprio, T., Heiskanen, A., Satomaa, T., Hiltunen, J. O., Miettinen, M., Arola, J. T., & Haglund, C. H. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00401 · Cited by 15
Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation
Cui, Y., Ma, X., Wang, F., Wang, H., Zhou, T., Chen, S., Tong, A., & Li, Y. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.09.015 · Cited by 15
Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal
Moog, S., Castinetti, F., Cao, C. D., Amar, L., Hadoux, J., Lussey‐Lepoutre, C., Borson‐Chazot, F., Vezzosi, D., Drui, D., Laboureau, S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab202 · Cited by 15
CT-based radiomics deep learning signatures for non-invasive prediction of metastatic potential in pheochromocytoma and paraganglioma: a multicohort study
Zhou, Y., Zhan, Y., Zhao, J., Zhong, L., Zou, F., Zhu, X., Zeng, Q., Nan, J., Gong, L., Tan, Y., et al. (2025) · Insights into Imaging · doi:10.1186/s13244-025-01952-4 · Cited by 14
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma
Jiménez, C., Chin, B. B., Noto, R. B., Dillon, J. S., Sólnes, L. B., Stambler, N., DiPippo, V. A., & Pryma, D. A. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0236 · Cited by 14
The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours
Juhlin, C. C. (2024) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-209060 · Cited by 14
Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation
Stigliano, A., Lardo, P., Cerquetti, L., Aschelter, A. M., Matarazzo, I., Capriotti, G., Schiavi, F., Marchetti, P., Nardone, M. R., Petrangeli, E., et al. (2018) · Medicine · doi:10.1097/md.0000000000010904 · Cited by 14
Pheochromocytoma: When to search a germline defect?
Buffet, A., Burnichon, N., Amar, L., & Gimenez‐Roqueplo, A. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.07.003 · Cited by 14
Whole Exome Sequencing Identifies Novel Genetic Alterations in Patients with Pheochromocytoma/Paraganglioma
Seo, S. H., Kim, J. H., Kim, M. J., Cho, S. I., Kim, S. J., Kang, H., Shin, C. S., Park, S. S., Lee, K. E., & Seong, M. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.756 · Cited by 14
Management of Adrenal Tumors in Pediatric Patients
Abib, S. D. C. V., & Weldon, C. B. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.11.012 · Cited by 14
A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review
Liu, Q., Wang, Y., Tong, D., Liu, G., Yuan, W., Zhang, J., Ye, J., Zhang, Y., Yuan, G., Feng, Q.-X., et al. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9469-4 · Cited by 15
Oncometabolite induced primary cilia loss in pheochromocytoma
O’Toole, S. M., Watson, D., Novoselova, T. V., Romano, L. E. L., King, P., Bradshaw, T. Y., Thompson, C. L., Knight, M. M., Sharp, T. V., Barnes, M. R., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0134 · Cited by 14
Recent progress in molecular classification of phaeochromocytoma and paraganglioma
Boehm, E., Gill, A. J., Clifton-Bligh, R. J., & Tothill, R. W. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101939 · Cited by 15
Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: A cohort study
Park, S. S., Ahn, C. H., Lee, S.-H., Lee, W., Kim, W. W., Lee, Y., Kim, S. J., Sung, T., Lee, K. E., Kim, J. H., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13791 · Cited by 13
Head and neck paragangliomas: Recent advances in translational and clinical research and guidelines for patient care
Richter, S., Constantinescu, G. A., Fancello, G., Paties, C. T., Mariani‐Costantini, R., & Sanna, M. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101951 · Cited by 13
Mixed corticomedullary tumor of the adrenal gland
Kimura, N., Motoyama, T., Saito, J., & Nishikawa, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1026918 · Cited by 12
Self-citation
Spermatic Cord Paraganglioma With Histologically Malignant Features
Kwon, A., Kang, H., An, H. J., Kim, G., Kim, T. H., Heo, J. H., Lee, H. J., & Hong, Y. K. (2016) · Urology · doi:10.1016/j.urology.2016.03.014 · Cited by 12
Mutation of the Cell Cycle Regulator p27kip1 Drives Pseudohypoxic Pheochromocytoma Development
Mohr, H., Ballke, S., Bechmann, N., Gulde, S., Malekzadeh‐Najafabadi, J., Peitzsch, M., Ntziachristos, V., Steiger, K., Wiedemann, T., & Pellegata, N. S. (2021) · Cancers · doi:10.3390/cancers13010126 · Cited by 12
Top Ten Oncocytic Head and Neck Lesions to Contemplate
Bullock, M. J., & Jiang, X. “. (2023) · Head and Neck Pathology · doi:10.1007/s12105-022-01520-y · Cited by 12
Long-term outcomes and prognostic factors of metastatic or recurrent pheochromocytoma and paraganglioma: a 20-year review in a single institution
Ishizaki, F., Taguchi, T., Murata, M., Hoshino, S., Toba, T., Takeda, K., Tasaki, M., Yamana, K., Kasahara, T., Hoshii, T., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-75354-9 · Cited by 11
Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma
Wang, Y., Chen, D., Pang, Y., Xu, X., Guan, X., & Liu, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.882906 · Cited by 11
Ratio-Metric Fluorescence/Colorimetric and Smartphone-Assisted Visualization for the Detection of Dopamine Based on Cu-MOF with Catecholase-like Activity
Guo, Y., Chen, M., Yang, T., & Wang, J. (2023) · Chemosensors · doi:10.3390/chemosensors11080431 · Cited by 11
Molecular classification and tumor microenvironment characteristics in pheochromocytomas
Qin, S., Xu, Y., Yu, S., Han, W., Fan, S., Ai, W., Zhang, K., Wang, Y., Zhou, X., Shen, Q., et al. (2023) · eLife · doi:10.7554/elife.87586 · Cited by 13
Establishment and evaluation of a novel biomarker‐based nomogram for malignant phaeochromocytomas and paragangliomas
Zhong, X., Ye, L., Su, T., Xie, J., Zhou, W., Jiang, Y., Jiang, L., Ning, G., & Wang, W. (2017) · Clinical Endocrinology · doi:10.1111/cen.13357 · Cited by 11
Prognostic significance of Ki-67 in assessing the risk of progression, relapse or metastasis in pheochromocytomas and paragangliomas
Luo, Z., Xu, Y., Liu, Y., Nan, F., Lei, Y., Ren, Y., & Li, L. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2478312 · Cited by 10
Identification of Predictors of Metastatic Potential in Paragangliomas to Develop a Prognostic Score (PSPGL)
Perez, D. Y. V. I., Martins-Filho, S. N., Soares, I. C., Siqueira, S. A. C., Alves, V. A. F., Assato, A. K., Yang, J. H., Almeida, M. Q., Fragoso, M. C. B. V., Fagundes, G. F. C., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae093 · Cited by 10
Expression of Glutamine Metabolism-Related and Amino Acid Transporter Proteins in Adrenal Cortical Neoplasms and Pheochromocytomas
Kim, H. M., & Koo, J. S. (2021) · Disease Markers · doi:10.1155/2021/8850990 · Cited by 10
A Critical Appraisal of Contemporary and Novel Biomarkers in Pheochromocytomas and Adrenocortical Tumors
Tsoli, M., Daskalakis, K., Kassi, E. N., Kaltsas, G., & Tsolakis, A. V. (2021) · Biology · doi:10.3390/biology10070580 · Cited by 10
Diagnosis and Outcome of Cardiac Paragangliomas: A Retrospective Observational Cohort Study in China
Dong, X., Meng, X., Zhang, T., Zhao, L. Y., Liu, F., Han, X., Liu, Y., Zhu, H., Zhou, X., Miao, Q., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.780382 · Cited by 10
Computerized tomography texture analysis of pheochromocytoma: relationship with hormonal and histopathological data
Leo, A. D., Vara, G., Paccapelo, A., Balacchi, C., Vicennati, V., Tucci, L., Pagotto, U., Selva, S., Ricci, C., Alberici, L., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01826-2 · Cited by 10
Dopamine-Secreting Paraganglioma in the Retroperitoneum
Matsuda, Y., Kimura, N., Yoshimoto, T., Sekiguchi, Y., Tomoishi, J., Kasahara, I., Hara, Y., & Ogawa, Y. (2016) · Endocrine Pathology · doi:10.1007/s12022-016-9457-0 · Cited by 10
Self-citation
Diagnosis and management of adrenal incidentaloma: use of clinical judgment and evidence in dialog with the patient
Yoshida, Y., Horiuchi, K., Otsuki, M., & Okamoto, T. (2023) · Surgery Today · doi:10.1007/s00595-023-02781-y · Cited by 13
Reappraisal of Neuroendocrine Tumor Classification of the Prostate Gland: Translating Molecular Insights into Clinical Practice
Lobo, A., & Liang Cheng, C. (2025) · Endocrine Pathology · doi:10.1007/s12022-025-09871-2 · Cited by 9
From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma
Parasiliti-Caprino, M., Bioletto, F., Lopez, C., Bollati, M., Maletta, F., Caputo, M., Gasco, V., Grotta, A. L., Limone, P., Borretta, G., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10061310 · Cited by 9
Antiproliferative effects of metformin in cellular models of pheochromocytoma
Meireles, C. G., de Lima, C. L., Oliveira, M. M. D. P., Miranda, R. A. D. R., Romano, L. E. L., Brashaw, T. Y.-S., Guerra, E. N. S., Neves, F. D. A. R., Chapple, J. P., Simeoni, L. A., et al. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111484 · Cited by 9
Progress in the diagnosis and treatment of paraganglioma
Wang, B., & Qiu, J. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.10.11 · Cited by 9
A rare case of multiple paragangliomas in the head and neck, retroperitoneum and duodenum: A case report and review of the literature
Kawanabe, S., Katabami, T., Oshima, R., Yanagisawa, N., Sone, M., & Kimura, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1054468 · Cited by 9
Self-citation
A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma: a study protocol
Inaki, A., Yoshimura, K., Murayama, T., Imai, Y., Kuribayashi, Y., Higuchi, T., Jinguji, M., Shiga, T., & Kinuya, S. (2017) · The Journal of Medical Investigation · doi:10.2152/jmi.64.205 · Cited by 9
Paraganglioma of the Spine: A Twenty-Years Clinical Experience of a High Volume Tumor Center
Pipola, V., Boriani, S., Bandiera, S., Righi, A., Bròdano, G. B., Terzi, S., Ghermandi, R., Tedesco, G., Evangelisti, G., Girolami, M., et al. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2019.05.037 · Cited by 9
The Role of Chromogranin A in Adrenal Tumors
Mirică, A., Bădărău, I. A., Stefanescu, A. M., Mirică, R., Paun, S. C., Stefan, D. C. A., & Păun, D. L. (2018) · Revista de Chimie · doi:10.37358/rc.18.3.6174 · Cited by 9
Malignant Intrarenal/Renal Pelvis Paraganglioma with Co-Occurring SDHB and ATRX Mutations
Irwin, T., Konnick, E. Q., & Tretiakova, M. (2019) · Endocrine Pathology · doi:10.1007/s12022-019-09594-1 · Cited by 8
Paediatric phaeochromocytoma and paraganglioma: A clinical update
Nazari, M. A., Jha, A., Kuo, M. J. M., Patel, M. A., Prodanov, T., Rosenblum, J. S., Talvacchio, S. K., Derkyi, A., Charles, K. M., & Pacák, K. (2023) · Clinical Endocrinology · doi:10.1111/cen.14955 · Cited by 8
HuR in pheochromocytomas and paragangliomas – overexpression in verified malignant tumors
Leijon, H., Salmenkivi, K., Heiskanen, I., Hagström, J., Louhimo, J. M., Heikkilä, P., Ristimaki, A. P., Paavonen, T., Metso, S., Mäenpää, H. O., et al. (2016) · Apmis · doi:10.1111/apm.12571 · Cited by 8
Predictors of outcome in phaeochromocytomas and paragangliomas
Nicolas, M. M., & Dahia, P. L. M. (2017) · F1000Research · doi:10.12688/f1000research.12419.1 · Cited by 8
Current views on paediatric phaeochromocytoma and paraganglioma with a focus on newest guidelines
Pamporaki, C., & Casey, R. T. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101957 · Cited by 7
Prognosis and tumor microenvironment in pseudohypoxic pheochromocytoma/paraganglioma
Ohmoto, A., Shigematsu, Y., Saito, R., Dobashi, A., Fujiwara, Y., Togashi, Y., Yonese, J., Inamura, K., & Takahashi, S. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-04009-x · Cited by 7
The evolving roles of pathologists in paragangliomas and pheochromocytomas
Mete, Ö., & Juhlin, C. C. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04379-w · Cited by 9
Pheochromocytoma-induced Subarachnoid and Intracerebral Hemorrhage
Agoubi, L. L., Khot, S. P., Failor, R. A., & Zern, N. K. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac176 · Cited by 7
Adrenal Pathology in the Adult: A Urological Pathologist’s Perspective
Hansel, D. E., & Reuter, V. E. (2016) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000120 · Cited by 6
Recurrent, bilateral, and metastatic pheochromocytoma in a young patient with Beckwith-Wiedemann syndrome: A genetic link?
Caza, T. N., Manwaring, J., & Riddell, J. (2017) · Canadian Urological Association Journal · doi:10.5489/cuaj.4297 · Cited by 7
Paraganglioma with a very rare presentation
Khare, M., Gupta, M., Sharma, U., & Garg, K. (2018) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_334_17 · Cited by 7
Metastatic pheochromocytomas and paragangliomas: where are we?
Prinzi, N., Corti, F., Torchio, M., Niger, M., Antista, M., Pagani, F., Beninato, T., Pulice, I., Rossi, R. E., Coppa, J. C., et al. (2022) · Tumori Journal · doi:10.1177/03008916221078621 · Cited by 7
Paraganglioma as a risk factor for bone metastasis
Yokomoto‐Umakoshi, M., Umakoshi, H., Tsuiki, M., Ogasawara, T., 佳歩, 廣., Tanabe, A., Tagami, T., Shimatsu, A., & Naruse, M. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0368 · Cited by 7
Self-citation
Inflammation in the neoplasms of the adrenal gland: Is there a prognostic role? An immunohistochemical study
Guadagno, E., Russo, D., Pignatiello, S., & De, M. D. B. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153070 · Cited by 7
Paraganglioma masquerading as a primary liver lesion: A rare entity discovered during surgery
Miller, M. E., Vietor, N. O., Park, E. J., Sweeney, S. P., Katz, M., & Vietor, R. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5310 · Cited by 7
Personalisierte Therapie des Phäochromozytoms
Schlegel, N., Meir, M., Reibetanz, J., Markus, C., Wiegering, A., & Faßnacht, M. (2023) · Die Chirurgie · doi:10.1007/s00104-023-01988-6 · Cited by 6
Long-term outcomes of abdominal paraganglioma
Choi, H. R., Yap, Z. Z., Choi, S. M., Choi, S. H., Kim, J. K., Lee, C. R., Lee, J., Jeong, J. J., Nam, K., Chung, W. Y., et al. (2020) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2020.99.6.315 · Cited by 6
Head and Neck Malignant Paragangliomas: Experience from a Single Institution
Ding, Y., Li, L., Han, D.-M., Wang, S., & Chen, X. (2021) · Ear Nose & Throat Journal · doi:10.1177/01455613211052338 · Cited by 6
A case of juvenile-onset pheochromocytoma with KIF1B p.V1529M germline mutation
Nezu, M., Hirotsu, Y., Amemiya, K., Katsumata, M., Watanabe, T., Takizawa, S., Inoue, M., Mochizuki, H., Hosaka, K., Oyama, T., et al. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0475 · Cited by 6
Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis
Green, B. L., Grant, R., Richie, C. T., Chatterjee, B., Melo, M. S. D., Barr, F. G., Pacák, K., Agarwal, S. K., & Nilubol, N. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0797 · Cited by 6
Whole transcriptome analysis of canine pheochromocytoma and paraganglioma
van den Berg, M. F., Kooistra, H. S., Grinwis, G. C. M., Nicoli, S. F., Golinelli, S., Stammeleer, L., van Wolferen, M. E., Timmermans‐Sprang, E. P. M., Zandvliet, M. M. J. M., van Steenbeek, F. G., et al. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1155804 · Cited by 6
Novel alternative tools for metastatic pheochromocytomas/paragangliomas prediction
Cui, Y., Zhou, Y., Gao, Y., Ma, X., Wang, Y., Zhang, X., Zhou, T., Chen, S., Lü, L., Zhang, Y., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02239-5 · Cited by 6
Malignant prediction in paragangliomas: analysis for clinical risk factors
Torres-Costa, M., Flores, B., Torregrosa, N. M., González, M., Ríos, A., Febrero, B., Flores, D., Rodríguez, P., Carbonell, P., Ortuño, M. I., et al. (2021) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-021-02222-9 · Cited by 6
Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study
Wang, L., Wei, X., Zhang, Q., & Li, F. (2022) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2022.151981 · Cited by 6
A novel diagnostic method of Raman spectroscopy for malignant pheochromocytoma/paraganglioma
Du, Y., Huang, Z. L., Wang, L., Huang, L., Cao, P., He, D., Zhang, Y., Wu, D., Yang, Z.-S., & Fan, J. (2016) · RSC Advances · doi:10.1039/c6ra18312c · Cited by 6
Clinicopathological and genomic analysis of pediatric pheochromocytoma and sympathetic paraganglioma
Kimura, N., Muroya, K., Yonamine, M., Takekoshi, K., SATO, T. A., Hirose, R., Sasaki, T., Tamai, K., Mabe, H., Kawashima, J., et al. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0584 · Cited by 5
Self-citation
Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study
Park, M., Park, S. S., Lee, B. H., Jang, J. S., Kim, W. W., Kim, S. J., Lee, Y.-M., Lee, K. E., Sung, T., Seong, M., et al. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0269 · Cited by 5
GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades
Watanabe, H., Fujishima, F., Yamazaki, Y., Imamura, M., Hijioka, S., Hara, K., Kuwahara, T., Yatabe, Y., Sakamoto, K., Shiga, H., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04098-2 · Cited by 5
Hereditary pheochromocytoma/paraganglioma syndrome with a novel mutation in the succinate dehydrogenase subunit B gene in a Japanese family: two case reports
Hirose, R., Tsurutani, Y., Sugisawa, C., Inoue, K., Suematsu, S., Nagata, M., Hasegawa, N., Kakuta, Y., Yonamine, M., Takekoshi, K., et al. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02852-z · Cited by 5
Self-citation
Clinicopathological study of adrenal pheochromocytoma and extra-adrenal paragangliomas with reference to GAPP and PASS scoring systems
Mondal, A., Sengupta, M., Dey, S., Kar, A., Maiti, K., Sarkar, D., & Chatterjee, U. (2024) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_859_23 · Cited by 5
Analysis of clinical and pathological characteristics of retroperitoneal paraganglioma and associated prognostic factors
Chun, C.-P., Song, L., Xu, G., Shi, Q. W., Li, F., & Jia, X. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27681 · Cited by 5
A Pathologist’s View: Molecular Profiles for Diagnosing Pheochromocytomas and Paragangliomas
Kimura, N. (2015) · International Journal of Endocrine Oncology · doi:10.2217/ije.15.16 · Cited by 5
Self-citation
Neuroendocrine Neoplasms, Olfactory Neuroblastomas and Paragangliomas of the Head and Neck
Klöppel, G., Franchi, A., & Matías‐Guiu, X. (2016) · Springer eBooks · doi:10.1007/978-3-662-49672-5_11 · Cited by 5
Aggressive Imaging Features in a Malignant Pheochromocytoma With a Novel Mutation of the SDHB Gene
Park, S., Lee, D. H., & Kim, H. S. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001729 · Cited by 5
Rectal Paraganglioma
Araki, T., Takeshita, S., Kawasaki, H., Kusumoto, K., Ohata, K., Shigematsu, K., & Shigeno, M. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1218-18 · Cited by 5
Locally Invasive Pheochromocytoma Combined with Primary Malignant Adrenal Lymphoma
Oraibi, O., Wharry, L. I., Lynn, A. A. A., Chaudhry, F., Jaume, J. C., & Jun, J. Y. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0221 · Cited by 5
Changes in the Size of a Ruptured Pheochromocytoma after Transcatheter Arterial Embolization
Ichikawa, T., Oyabu, C., Minamida, M., Ichijo, Y., Hashimoto, Y., Asano, M., Iwase, H., Tanaka, T., & Fukui, M. (2021) · Case Reports in Medicine · doi:10.1155/2021/5568978 · Cited by 5
Colorectal paragangliomas with immunohistochemical deficiency of succinate dehydrogenase subunit B
Kimura, N., Ishikawa, M., & Shigematsu, K. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0630 · Cited by 5
Self-citation
The Classic, the Trendy, and the Refashioned: A Primer for Pathologists on What Is New in Familial Endocrine Tumor Syndromes
Ababneh, E. I., & Nosé, V. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000370 · Cited by 5
The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas
Ohmachi, Y., Yamamoto, M., Inaba, Y., Makino, S., Urai, S., Matsumoto, R., Bando, H., Kanie, K., Tsujimoto, Y., Motomura, Y., et al. (2024) · Endocrine · doi:10.1007/s12020-023-03681-4 · Cited by 5
Continuous Hemodiafiltration for Pheochromocytoma Crisis with a Positive Outcome
Koizumi, G., Saiki, R., Kurokawa, I., Mikura, K., Iida, T., Murai, N., Kaji, M., Hashizume, M., Kigawa, Y., Endo, K., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2991-19 · Cited by 5
Increasing Catecholamine Secretion Through NPY in Pheochromocytomas With False-Negative 123I-MIBG Scintigraphy
Ruike, Y., Suzuki, S., & Yokote, K. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005139 · Cited by 4
Prognostic markers in pheochromocytomas/paragangliomas: the role of histopathology, SDHB, MAML3 and MCM6 expression
Yaldır, E., Cengiz, B. B., Mülkem, O. F., Bilgin, M., & Açıkalın, M. F. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02610-8 · Cited by 4
Preliminary evaluation of GLP-1R PET in the diagnosis and risk stratification of pheochromocytomas
Li, M., Liu, Y., XU, Y., LI, Y., Pan, D.-Y., WANG, L., Yan, J., Wang, X., YANG, R., & Yang, M. (2019) · Neoplasma · doi:10.4149/neo_2019_190227n163 · Cited by 4
Succinate dehydrogenase‐deficient malignant paraganglioma complicated by succinate dehydrogenase‐deficient renal cell carcinoma
Yamaguchi, Y., Yokoyama, M., Takemoto, A., Nakamura, Y., Fukuda, S., Uehara, S., Tanaka, H., Yoshida, S., Matsuoka, Y., & Fujii, Y. (2022) · IJU Case Reports · doi:10.1002/iju5.12520 · Cited by 4
Neurofibromatosis-related phaeochromocytoma: two cases with large tumours and elevated plasma methoxytyramine
Teasdale, S., & Reda, E. S. (2015) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-15-0059 · Cited by 4
Pheochromocytoma Diagnosed during the Treatment of Diffuse Alveolar Hemorrhage, a Diagnostic Necessity before Using High-dose Glucocorticoids
Nezu, M., Kobayashi, H., Shiozaki, M., Katsumata, M., Takizawa, S., Tsutsui, T., Nukui, I., Miyashita, Y., Oyama, T., & Inoue, M. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6827-20 · Cited by 4
Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation
Kamai, T., Murakami, S., Arai, K., Nishihara, D., Uematsu, T., Ishida, K., & Kijima, T. (2022) · BMC Cancer · doi:10.1186/s12885-022-09415-5 · Cited by 4

Authors: Kimura, N., Takayanagi, R., Takizawa, N., Itagaki, E., Katabami, T., Kakoi, N., Rakugi, H., Ikeda, Y., Tanabe, A., Nigawara, T., Ito, S., Kimura, I., Naruse, M., & _, _.
Affiliations: National Hospital Organization (JP)
Kyushu University (JP)
Kansai Medical University (JP)
Kyorin University (JP)
St. Marianna University School of Medicine (JP)
Miyagi Prefectural Hospital Organization (JP)
The University of Osaka (JP)
Nihon University Itabashi Hospital (JP)
Tokyo Women's Medical University (JP)
Hirosaki University (JP)
Tohoku University (JP)
Ministry of Health Labour and Welfare (JP)
Kyoto Medical Center (JP)
ORCID: Kimura, Noriko
Takizawa, Nae
Rakugi, Hiromi
Ikeda, Yukihiro
Tanabe, Akiyo
Nigawara, Takeshi
Ito, Sadayoshi
Naruse, Mitsuhide
Venue: Endocrine Related Cancer
Publisher: Bioscientifica
Published: 2014-02-12
Volume: 21
Issue: 3
Pages: 405-414
ISSN: 1351-0088 (ISSN-L)
1479-6821
DOI: 10.1530/erc-13-0494
OpenAlex: W2153367841
Cited by: 393
References: 25
Citations by year: 2026: 29 · 2025: 45 · 2024: 42 · 2023: 41 · 2022: 51 · 2021: 39 · 2020: 24 · 2019: 27 · 2018: 27 · 2017: 27 · 2016: 21 · 2015: 10 · 2014: 6
FWCI: 21.14
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Endocrine Related Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: Shimane University
Tokyo Medical and Dental University
Jikei University School of Medicine
Topics: Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: pheochromocytoma, paraganglioma, metastasis prediction, tumor grade, SDHB immunohistochemistry, Ki-67 labelling index, comedo necrosis, capsular invasion, survival
MeSH terms: Adrenal Gland Neoplasms, Adult, Aged, Aged, 80 and over, Catecholamines, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Male, Middle Aged, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Prognosis, Succinate Dehydrogenase, Biomarkers, Tumor, Survival Rate, Case-Control Studies, Young Adult, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks